BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 11567783)

  • 1. Positron emission tomography shows that impaired frontal lobe functioning in Parkinson's disease is related to dopaminergic hypofunction in the caudate nucleus.
    Brück A; Portin R; Lindell A; Laihinen A; Bergman J; Haaparanta M; Solin O; Rinne JO
    Neurosci Lett; 2001 Sep; 311(2):81-4. PubMed ID: 11567783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study.
    Rinne JO; Portin R; Ruottinen H; Nurmi E; Bergman J; Haaparanta M; Solin O
    Arch Neurol; 2000 Apr; 57(4):470-5. PubMed ID: 10768619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
    Rinne OJ; Nurmi E; Ruottinen HM; Bergman J; Eskola O; Solin O
    Synapse; 2001 Jun; 40(3):193-200. PubMed ID: 11304757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease.
    Broussolle E; Dentresangle C; Landais P; Garcia-Larrea L; Pollak P; Croisile B; Hibert O; Bonnefoi F; Galy G; Froment JC; Comar D
    J Neurol Sci; 1999 Jul; 166(2):141-51. PubMed ID: 10475108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism.
    Carbon M; Ma Y; Barnes A; Dhawan V; Chaly T; Ghilardi MF; Eidelberg D
    Neuroimage; 2004 Apr; 21(4):1497-507. PubMed ID: 15050574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain 6-[18F]fluorodopa metabolism in early and late onset of Parkinson's disease studied by positron emission tomography.
    Nagasawa H; Tanji H; Itoyama Y; Saito H; Kimura I; Fujiwara T; Iwata R; Itoh M; Ido T
    J Neurol Sci; 1996 Dec; 144(1-2):70-6. PubMed ID: 8994106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy.
    Jokinen P; Brück A; Aalto S; Forsback S; Parkkola R; Rinne JO
    Parkinsonism Relat Disord; 2009 Feb; 15(2):88-93. PubMed ID: 18434233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personality correlates of [18F]dopa striatal uptake: results of positron-emission tomography in Parkinson's disease.
    Menza MA; Mark MH; Burn DJ; Brooks DJ
    J Neuropsychiatry Clin Neurosci; 1995; 7(2):176-9. PubMed ID: 7626960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease.
    Leenders KL; Salmon EP; Tyrrell P; Perani D; Brooks DJ; Sager H; Jones T; Marsden CD; Frackowiak RS
    Arch Neurol; 1990 Dec; 47(12):1290-8. PubMed ID: 2123623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Young-onset Parkinson disease with and without parkin gene mutations: a fluorodopa F 18 positron emission tomography study.
    Thobois S; Ribeiro MJ; Lohmann E; Dürr A; Pollak P; Rascol O; Guillouet S; Chapoy E; Costes N; Agid Y; Remy P; Brice A; Broussolle E;
    Arch Neurol; 2003 May; 60(5):713-8. PubMed ID: 12756135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data.
    Sawle GV; Playford ED; Burn DJ; Cunningham VJ; Brooks DJ
    Arch Neurol; 1994 Mar; 51(3):237-43. PubMed ID: 8129633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET.
    Nurmi E; Bergman J; Eskola O; Solin O; Vahlberg T; Sonninen P; Rinne JO
    Synapse; 2003 Jun; 48(3):109-15. PubMed ID: 12645035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopaminergic modulation of striato-frontal connectivity during motor timing in Parkinson's disease.
    Jahanshahi M; Jones CR; Zijlmans J; Katzenschlager R; Lee L; Quinn N; Frith CD; Lees AJ
    Brain; 2010 Mar; 133(Pt 3):727-45. PubMed ID: 20305278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms.
    Otsuka M; Ichiya Y; Kuwabara Y; Hosokawa S; Sasaki M; Yoshida T; Fukumura T; Masuda K; Kato M
    J Neurol Sci; 1996 Mar; 136(1-2):169-73. PubMed ID: 8815166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging in Parkinson's disease: the role of monoamines in behavior.
    Brooks DJ; Piccini P
    Biol Psychiatry; 2006 May; 59(10):908-18. PubMed ID: 16581032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical utility of (18)F-DOPA-PET in movement disorders. A systematic review].
    Puñal-Riobóo J; Serena-Puig A; Varela-Lema L; Alvarez-Páez AM; Ruano-Ravina A
    Rev Esp Med Nucl; 2009; 28(3):106-13. PubMed ID: 19558950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET.
    Brooks DJ; Salmon EP; Mathias CJ; Quinn N; Leenders KL; Bannister R; Marsden CD; Frackowiak RS
    Brain; 1990 Oct; 113 ( Pt 5)():1539-52. PubMed ID: 2123119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 6-[18F]fluorodopa metabolism in patients with hemiparkinsonism studied by positron emission tomography.
    Nagasawa H; Saito H; Kogure K; Hatazawa J; Itoh M; Fujiwara T; Watanuki S; Seo S; Iwata R; Ido T
    J Neurol Sci; 1993 Apr; 115(2):136-43. PubMed ID: 8482975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine storage capacity in caudate and putamen of patients with early Parkinson's disease: correlation with asymmetry of motor symptoms.
    Kumakura Y; Gjedde A; Danielsen EH; Christensen S; Cumming P
    J Cereb Blood Flow Metab; 2006 Mar; 26(3):358-70. PubMed ID: 16079784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT.
    Nurmi E; Ruottinen HM; Kaasinen V; Bergman J; Haaparanta M; Solin O; Rinne JO
    Ann Neurol; 2000 Jun; 47(6):804-8. PubMed ID: 10852547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.